Formación Académica y Profesional
Licenciado Matemáticas (Especialidad Fundamentales) por UCM, MBA Executive, MBA Financial Markets, Project Management Excellence Certified
Financial Markets Services Consulting, IT CIO ACO Grupo Santander, IBM Global Services Principal, Electronic Data System Client Ececutive


The mathematician of the Complutense University of Madrid, José-Vidal Ruiz Varela, argues that Europe must raise its borrowing limit, leaving its deflationary policy. Meanwhile, USA must correct debt and raise the interest rates. Raising the interest rates in the USA and dropping them in Europe, recovers the European domestic demand and EE.UU may return to invest in Europe, with a stronger dollar, without any problem, generating hundreds of thousands of Jobs

Curso Superior de #AnálisisDeDatos Contacto :

Curso Superior de #AnálisisDeDatos Contacto :
40 horas. Profesor : José - Vidal Ruiz Varela

Clases Particulares para hacer crecer tu Negocio. #Bigdata #DesarrolloCognitivo

Clases Particulares para hacer crecer tu Negocio. #Bigdata #DesarrolloCognitivo
Profesor : José - Vidal Ruiz Varela

#Bigdata y #Desarrollo #Cognitivo para Personas entre 15 y 65 años

#Bigdata y #Desarrollo #Cognitivo para Personas entre 15 y 65 años
Profesor : José - Vidal Ruiz Varela

Agenda Macro

Agenda de Economía y Finanzas en el Calendario Económico de Español.


Principales Materias Primas

Commodities entregados por

Cotización de las Principales divisas en tiempo real

Cotización de las Principales divisas en tiempo real
e-mail :

Principales Índices Mundiales

El IBEX 35 y los Índices del Mundo son proveídos por Español.

Johnson & Johnson profit rises

NEW YORK (MarketWatch)
Johnson & Johnson said Tuesday its fourth-quarter profit increased to $2.57 billion, or 91 cents a share, from $218 million, or 8 cents a share, in the year-ago period
Excluding one-time items, Johnson & Johnson earned $1.19 a share in the latest quarter, The health care product maker's sales rose 8% to $17.56 billion
Wall Street analysts expected Johnson & Johnson to earn $1.17 a share on revenue of $17.68 billion, according to a survey by FactSet
Looking ahead, Johnson & Johnson expects to deliver "sustainable growth as we enter 2013."

1 comentario:

El Genio dijo...

By Peter Loftus
(Updates with additional details throughout.)

Johnson & Johnson /quotes/zigman/230812/quotes/nls/jnj JNJ -0.94% reported a surge in fourth-quarter earnings from a year-earlier period that was weighed down by legal costs, while an acquisition helped sales rise 8%.

The health-care giant, which is trying to bounce back from a series of product recalls, had lighter-than-expected quarterly sales and issued a forecast for 2013 earnings that fell slightly short of Wall Street expectations.

J&J reported its quarterly numbers ahead of a meeting with analysts and investors in New York where executives plan to spotlight the company's biggest business unit, medical devices and diagnostics, newly enlarged by last year's $20 billion purchase of device maker Synthes.

J&J's new chief executive, Alex Gorsky, has said his top priorities are restoring the supply of over-the-counter medicines--including Tylenol--that were subject to a series of recalls, integrating the Synthes purchase, and building on recent momentum in J&J's pharmaceutical unit, which has launched several new drugs.

For the fourth quarter, J&J earned $2.57 billion, or 91 cents a share, compared with $218 million, or 8 cents a share, a year earlier. The year-earlier quarter included hefty charges related to litigation over J&J's recall of hip-replacement parts and other items, while the latest quarter included a lesser amount of similar charges.

Excluding one-items in both periods, per-share earnings rose to $1.19 from $1.13.

Sales rose 8% to $17.56 billion, with the Synthes deal contributing 5.6 percentage points of growth.

J&J was expected to earn $1.17 per share, excluding certain one-time items, on revenue of $17.67 billion for the fourth quarter, according to mean estimates of analysts surveyed by Thomson Reuters.

For full-year 2013, J&J expects to earn $5.35 to $5.45 per share, excluding certain items. Analysts were expecting earnings to rise 8% to $5.49 per share on a 7% increase in revenue to $72.17 billion.

Medical device and diagnostics sales rose 13.7% to $7.38 billion in the fourth quarter. Pharmaceutical sales rose 7.1% to $6.53 billion, while consumer-healthcare sales fell 0.4% to $3.65 billion.